HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

ClinicalTrials.gov ID: NCT07575308

Public ClinicalTrials.gov record NCT07575308. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Study identification

NCT ID: NCT07575308
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alnylam Pharmaceuticals; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Interventions

ALN-6400 Drug

Drug

Eligibility (public fields only)

Age range: 16 Years to 45 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 30, 2026 (Actual)
Primary completion: Jun 30, 2027 (Estimated)
Completion: Nov 29, 2028 (Estimated)
Last update posted: Sep 18, 2026

2026 – 2028

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
Clinical Trial Site	Orange	California	92868	Recruiting
Clinical Trial Site	San Diego	California	92123	Recruiting
Clinical Trial Site	San Francisco	California	94143	Recruiting
Clinical Trial Site	Miami	Florida	33024	Recruiting
Clinical Trial Site	Lexington	Kentucky	40536	Recruiting
Clinical Trial Site	Pittsburgh	Pennsylvania	15213	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07575308, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 18, 2026 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07575308 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →